PHARMA | PHARMANIAGA BHD

0.425 (-2.3%)
3

T-O (am): 0.435 (08:59:00)
Last updated: 17:00

Fundamental
Technical
Total Score

PHARMA | PHARMANIAGA BHD

iSaham Fundamental Trend

FCON: | Sharpe Ratio: | LTS:


Quarter Reports

Chart:

Select columns required and click "Update" to save your preferences

Ann. Date Qtr. Date Q FYE Revenue [M] PBT [M] NP [M] NPM DPS EPS R. QoQ R. YoY E. QoQ E. YoY TTM
EPS
Adj.
[M]
NP [M]
(adj)
NPM
(adj)
EPS
(adj)
E. QoQ
(adj)
E. YoY
(adj)
TTM EPS
(adj)
27 May 24 Q1 Mar 24 1 31 Dec 24 964.96 39.04 25.65 2.7% 0.00 1.78 22.2% 9.6% 178.4% 868.5%
29 Feb 24 Q4 Dec 23 4 31 Dec 23 789.81 -22.10 -32.72 -4.1% 0.00 -2.39 10.8% 8.4% 33.7% 94.9%
29 Nov 23 Q3 Sep 23 3 31 Dec 23 885.49 -56.26 -49.34 -5.6% 0.00 -3.67 4.3% 4.2% 2616.0% 672.6%
11 Aug 23 Q2 Jun 23 2 31 Dec 23 848.73 6.34 1.96 0.2% 0.00 0.15 3.6% 11.5% 25.9% 171.6%
18 May 23 Q1 Mar 23 1 31 Dec 23 880.45 9.19 2.65 0.3% 0.00 0.20 2.1% 8.5% 100.4% 90.5%
27 Feb 23 Q4 Dec 22 4 31 Dec 22 862.72 -638.39 -644.39 -74.7% 0.00 -49.19 6.7% 21.2% 7578.1% 853.9%
24 Nov 22 Q3 Sep 22 3 31 Dec 22 924.68 15.59 8.62 0.9% 0.60 0.66 21.5% 56.6% 1093.5% 82.7%
19 Aug 22 Q2 Jun 22 2 31 Dec 22 761.10 4.52 0.72 0.1% 0.50 0.06 20.9% 35.3% 97.4% 94.7%
20 May 22 Q1 Mar 22 1 31 Dec 22 962.17 37.44 27.73 2.9% 0.80 2.12 35.2% 21.3% 67.5% 19.9%
17 Feb 22 Q4 Dec 21 4 31 Dec 21 711.72 125.09 85.47 12.0% 5.00 6.53 66.6% 12.2% 71.5% 1450.1%
19 Nov 21 Q3 Sep 21 3 31 Dec 21 2,132.68 98.22 49.84 2.3% 2.00 3.81 81.2% 241.3% 263.6% 3356.0%
20 Aug 21 Q2 Jun 21 2 31 Dec 21 1,177.12 22.24 13.70 1.2% 1.50 1.05 48.4% 82.3% 40.8% 37.3%
21 May 21 Q1 Mar 21 1 31 Dec 21 793.50 31.52 23.14 2.9% 4.00 8.84 25.0% 3.2% 465.4% 3.3%
17 Mar 21 Q4 Dec 20 4 31 Dec 20 634.58 -13.51 -6.33 -1.0% 1.00 -2.42 1.6% 11.3% 539.0% 96.5%
19 Nov 20 Q3 Sep 20 3 31 Dec 20 624.80 4.09 1.44 0.2% 1.50 0.55 3.2% 12.8% 85.5% 199.8%
19 Aug 20 Q2 Jun 20 2 31 Dec 20 645.76 14.33 9.98 1.6% 2.50 3.82 21.2% 7.3% 55.5% 7.5%
19 May 20 Q1 Mar 20 1 31 Dec 20 819.92 30.88 22.40 2.7% 6.00 8.57 14.6% 4.3% 112.5% 14.2%
20 Feb 20 Q4 Dec 19 4 31 Dec 19 715.68 -238.47 -178.60 -24.9% 0.00 -68.45 0.2% 19.9% 37230.6% 4125.2%
20 Nov 19 Q3 Sep 19 3 31 Dec 19 716.85 3.88 0.48 0.1% 0.00 0.18 19.1% 23.0% 94.8% 91.1%
23 Aug 19 Q2 Jun 19 2 31 Dec 19 601.89 12.48 9.28 1.5% 2.50 3.56 23.4% 2.6% 52.7% 47.2%
16 May 19 Q1 Mar 19 1 31 Dec 19 786.11 30.24 19.62 2.5% 6.00 7.53 31.8% 28.2% 342.1% 9.6%
21 Feb 19 Q4 Dec 18 4 31 Dec 18 596.64 11.94 4.44 0.7% 2.00 1.71 2.4% 3.9% 17.7% 23.9%
17 Aug 18 Q2 Jun 18 2 31 Dec 18 582.73 11.97 5.39 0.9% 4.00 2.08 5.7% 12.5% 69.3% 43.3%
16 May 18 Q1 Mar 18 1 31 Dec 18 617.92 28.71 17.59 2.9% 5.00 6.77 0.8% 0.1% 19.0% 7.1%
27 Feb 18 Q4 Dec 17 4 31 Dec 17 613.20 19.87 21.70 3.5% 6.00 8.36 6.7% 5.2% 506.1% 2695.7%
15 Nov 17 Q3 Sep 17 3 31 Dec 17 574.50 15.27 3.58 0.6% 5.00 1.38 10.9% 11.5% 62.4% 72.6%
16 Aug 17 Q2 Jun 17 2 31 Dec 17 517.97 10.15 9.52 1.8% 4.00 3.67 16.2% 2.6% 49.7% 36.5%
16 May 17 Q1 Mar 17 1 31 Dec 17 618.29 27.78 18.92 3.1% 4.00 7.30 6.1% 10.6% 2363.5% 3.0%
21 Feb 17 Q4 Dec 16 4 31 Dec 16 582.82 4.07 -0.84 -0.1% 3.00 -0.32 13.1% 14.3% 106.4% 105.2%
21 Nov 16 Q3 Sep 16 3 31 Dec 16 515.22 19.92 13.06 2.5% 4.00 5.04 3.1% 1.8% 12.9% 34.6%
19 Aug 16 Q2 Jun 16 2 31 Dec 16 531.80 21.49 14.99 2.8% 5.00 5.79 4.9% 3.7% 18.4% 7.5%
13 May 16 Q1 Mar 16 1 31 Dec 16 559.20 26.54 18.38 3.3% 4.00 7.10 17.8% 18.5% 14.4% 42.2%
15 Feb 16 Q4 Dec 15 4 31 Dec 15 680.15 23.72 16.06 2.4% 7.00 6.20 29.7% 8.5% 19.6% 56.2%
26 Nov 15 Q3 Sep 15 3 31 Dec 15 524.41 25.34 19.97 3.8% 9.00 7.71 2.3% 4.5% 23.1% 33.5%
17 Aug 15 Q2 Jun 15 2 31 Dec 15 512.85 25.06 16.22 3.2% 7.00 6.26 8.7% 2.3% 49.0% 1.5%
18 May 15 Q1 Mar 15 1 31 Dec 15 471.90 38.61 31.79 6.7% 7.00 12.28 24.8% 0.7% 13.4% 21.3%
23 Feb 15 31/12/14 4 31/12/14 627.10 37.85 36.70 5.8% 12.00 14.18 24.9% 10.4% 145.4% 76.3%

Historical Dividends

Financial Ratios

EPS -3.78 sen
Trailing PE (Sector Median: 19.1) 0.0
PEG 0.0
Altman Z 1.1
Beaver -0.024
Current Ratio 0.59
Debt-Equity (DE) Ratio -8.49
FCF Yield -10.23 %
Revenue QoQ 22.18 %
Revenue YoY 9.6%
Profit QoQ 178.38 %
Profit YoY 868.5 %
Profit Margin (Sector Median: 2.6) -1.56 %
ROE (ROIC: 37.08) 20.01 %
Dividend Per Share (DPS) 0.0 sen
Dividend Yield (DY) 0.0 %

Adjusted Financial Ratios

Ratios below have been recalculated after adjusting for One Off Gain/Loss detected from Quarterly reports

EPS
Trailing PE (Sector Median: 19.1)
Profit QoQ
Profit YoY
Profit Margin (Sector Median: 2.6)
ROE (ROIC: 37.2)
Altman Z

Fair Value

Weighted Average Fair Value:

Discounted Cash Flow (DCF) 5% Growth
Discounted Cash Flow (DCF) 10% Growth
Relative Valuation
Average Analysts FV based on 2 rating(s)
Graham Formula
Graham Number
Net Tangible Asset (NTA) -0.19
Consistent QR FV
The Fair Value numbers are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The figures shown here should be taken as educational purposes only

Advanced Calculators

Calculate the fair value of the stock based on expected growth / risk, contract / award value, forecasted profit or forecasted revenue.

Forward PE FV Calculator
Latest Profit (adjusted) [M] 25.65
Expected Profit (Next QR) [M]
Expected Profit (After QR above) [M]
Expected Profit (After QR above) [M]
Estimated Fair Value
Growth/Risk Fair Value Calculator
Expected growth (%)
Estimated downside / risk (%)
Estimated New DCF Fair Value
Contract/Award Contribution Calculator
Contract/Award Value (in Million)
Estimated Contribution to Stock Price
Estimated New DCF Fair Value
Profit-Based Calculator
Expected Profit (M)
for Year
Estimated New DCF Fair Value
Revenue-Based Calculator
Expected Revenue (M)
for Year
Estimated New DCF Fair Value
Market Pricing
Expected Profit (M) 330.12
Expected Revenue (M) 31439.92
Expected Growth (%) 38.0
The Fair Value calculated using this calculators are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The purpose of this tool is to help investor to quickly calculate their own expected Fair Value based on their own research

Directors Share Purchases (Beta)


No transaction in the last 2 months.

Summary


Market Cap: 612 M.

Number of Shares: 1441 M.

Adjusted Float: 39.5%.

Stock highly correlated with

SOLUTN (82%)

NIHSIN (77%)

ASB (75%)

FPGROUP (75%)

Pharmaniaga Berhad, through its subsidiaries, operates as an integrated healthcare company. It is engaged in the logistics and distribution; sale and marketing; and research, development, and manufacture of generic pharmaceuticals, as well as the supply of medical products and services; hospital equipping; and provision of information technology solutions. It is also involved in the sale and distribution of portable medical devices; contract manufacturing; and distribution and trade of pharmaceuticals products, food supplements, and diagnostics products. Pharmaniaga sells its products and services to the public and private sectors primarily in Malaysia and Indonesia. The company was founded in 1994 and is based in Shah Alam, Malaysia. Pharmaniaga Bhd operates as a member of UEM Group.

Sectors: Trading & Services, Healthcare, Pharmaceuticals, Post MCO, Vaccine, Penny Stocks

Code: 7081

Website: http://www.pharmaniaga.com/

Related Links: Bursa | Annual Report | Announcement

Warrant Info:

No warrants listed

This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.
This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.